# MicuRx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/micurx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.micurx.com
- Total disclosed funding: $255M
- Latest round: Series E (Dec 21, 2020)
- Investors on record: 17

## About

Founded in 2012 and based in Shanghai, China, MicuRx Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the R&D and commercialization of new drugs for infectious diseases. The company was established by Dr. Zhengyu Yuan and Dr. Mikhail F. Gordeev. In August 2022, the company was listed on Shanghai Stock Exchange under the number 688373.
The company provides new drugs for infections caused by multidrug-resistant bacteria. The company's first commercialization application drug, contezolid, was treated for drug-resistant Gram-postive bacteria caused by skin and soft tissue infection. And contezolid was approved new drug application by China National Medical Products Administration (NMPA) in June 2021.
The company generates revenue by researching and developing antibacterial drugs and other related products.

## Funding rounds

- Series E, Dec 21, 2020, $107M — Legend Capital, Detong Capital, Korea Investment Partners, Founder H Fund, China Merchants Securities, Yingke Private Equity, Suzhou Zhongtai Venture Capital
- Series D, Aug 5, 2020, $43M — Zero2IPO Ventures, Huagai Capital, Sinopharm-CICC Capital
- Series D, Dec 6, 2017, $15M — BVCF Capital, Delian Capital
- Series C, Sep 26, 2016, $55M — GP Capital, 3E Bioventures Capital, GP TMT Capital, Delian Capital
- Series B, Aug 22, 2013, $25M — Devon Park Bioventures, 5Y Capital, BVCF Capital
- Series A, Jun 25, 2007, $10M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series B
- BVCF Capital — Series B, Series D
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series C
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series C
- GP TMT Capital — Series C
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series C, Series D
- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series D
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series D
- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series D
- Legend Capital — Series E
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series E
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series E
- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Series E
- China Merchants Securities — Series E
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series E
- Suzhou Zhongtai Venture Capital — Series E